The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly
emerging a promising new treatment for haematological and non-haematological …

Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …

Antibodies (Abs) containing two different antigen-binding sites in one molecule are called
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …

The dynamic and versatile nature of diseases such as cancer has been a pivotal challenge
for developing efficient and safe therapies. Cancer treatments using a single therapeutic …

Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …

The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …

Breast cancer is one of the most prevalent malignancies in women worldwide. Early-stage
breast cancer is considered a curable disease; however, once distant metastasis occurs, the …

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …